University Of Michigan Ann Arbor

Researchers showed superiority of Amitiza over placebo for improving abdominal pain, bloating and composite endpoints including stool frequency in patients with constipation-predominant irritable bowel syndrome, according to post hoc analyses of two pivotal phase 3 randomized controlled trials.

In this guest commentary, Peter D. Higgins, MD, associate professor of internal medicine at University of Michigan Health System, discusses the work of cell biologist Yoshinori Ohsumi , PhD — who was awarded the 2016 Nobel Prize in Physiology or Medicine for his discoveries of the mechanisms underlying autophagy — and its significance in understanding the development of inflammatory bowel disease.

Three distinct molecular subtypes of prostate cancer exist and correlate with distant metastasis–free survival, according to research presented at the ASTRO Annual Meeting.

Black men who have ever smoked tobacco and drank alcohol have the highest incidence of esophageal squamous cell carcinoma compared with other races and women, according to recent study data.

Results from two retrospective studies recently published in Gastrointestinal Endoscopy present differing conclusions on the effectiveness of through-the-scope clips for endoscopic closure of iatrogenic colonic perforations, one of which suggests that endoscopic suturing may be a more effective strategy.

Lycera has initiated a phase 2 clinical trial of LYC-30937-Enteric Coated in patients with ulcerative colitis, according to a press release.

Recurrence of thyroid cancer may be identified with more imaging, but imaging may not increase survival rates, recent findings show.

Esophageal-directed hypnotherapy was well tolerated and improved symptoms and quality of life in patients with functional heartburn in a pilot study.

NEW ORLEANS — More research is needed on the use of SGLT2 inhibitors in patients with diabetes given the potential risk for diabetic ketoacidosis and bone fractures, according to Rodica Busui, MD, PhD, of the University of Michigan Health System.

The FDA Arthritis Advisory Committee today voted 26-0 in favor of recommending the approval of ABP 501, Amgen’s proposed biosimilar to AbbVie’s Humira.